Market Access

A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

Digging a little deeper into the drug class phenomenon reveals some interesting takeaways on a smaller subgroup of users.

How chain and local closures are impacting healthcare access.

Finding the optimal balance in pharmacy benefit manager reform.

A look at the actionable steps needed to elicit change.

A cross-sectional study investigates the impact of Dobbs v Jackson’s Women’s Health Organization on national support and personal interest.

What factors influence their likelihood of receiving this form of obesity treatment?

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

While the program could be a good option for many, it's not a panacea.

A crash course on the bubble itself, including therapeutic areas most affected.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

The proposal aims to reduce out-of-pocket costs for a number of weight loss medications by 95%.

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

Tips for pharmacies with the reimbursement blues.

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.